Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 13/20 | 0.38 |
| ▸ | DRD3 | P35462 | 13/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482915 | 0.87 | PER2 (0.39) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL2994194 | 0.86 | PER2 (0.36) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL5482922 | 0.82 | SMYD2 (0.38) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL3757378 | 0.79 | SMYD2 (0.37) | PER2SMYD2SCN9A | |
| SCHEMBL3760372 | 0.79 | SMYD2 (0.36) | PER2SMYD2SCN9A | |
| SCHEMBL3745187 | 0.78 | MAPT (0.37) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL2988859 | 0.77 | SMYD2 (0.38) | SMYD2 | |
| SCHEMBL3002014 | 0.75 | F10 (0.43) | — | |
| SCHEMBL3002017 | 0.75 | F10 (0.43) | — | |
| SCHEMBL21595114 | 0.75 | PER2 (0.37) | PER2DRD2DRD3KCNH2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | PER2 2897/4885DRD2 2776/4885DRD3 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.